Source:Cell Reports
Author(s): Sunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Anastasia K. Yocum, Harika Gundlapalli, Yasmine White, Ari Firestone, Xuhong Cao, Saravana M. Dhanasekaran, Jeanne A. Stuckey, Gideon Bollag, Kevin Shannon, Nils G. Walter, Chandan Kumar-Sinha, Arul M. Chinnaiyan
Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant KRAS-dependent cells and AGO2 overexpression enhances KRASG12V-mediated transformation. Using AGO2−/− cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.
Graphical abstract
Teaser
Shankar et al. show that RAS interacts with AGO2, a key component of the RNA-silencing machinery. Interaction of oncogenic KRAS with AGO2 in the endoplasmic reticulum inhibits AGO2 function, elevates mutant KRAS protein levels, and enhances cellular transformation. AGO2 is required for maximal KRAS-mediated oncogenesis.from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1PWo2Cs
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου